Skip to main content
Download PDF

Association of telomerase reverse transcriptase gene rs10069690 variant with cancer risk: an updated meta-analysis

BMC Cancer volume 24, Article number: 1059 (2024) Cite this article

Abstract

Objective

Existing evidence suggests telomerase activation is a crucial step in tumorigenesis. The telomerase reverse transcriptase (TERT), encoded by the human TERT gene, is critical for telomerase expression. The TERT rs10069690 (C > T) variant was identified to be associated with the risk of cancer, however, there have been inconsistent results. Therefore, we performed a comprehensive meta-analysis aiming to clarify the association between this variant and cancer susceptibility.

Methods

We conducted literature search in PubMed, EMbase, MEDLINE and Cochrane Library up to April 30, 2024. Overall, there are 55 studies involving 334,196 patients with cancer and 741,187 controls included in the present study. All statistical analyses were performed by STATA software (version 11.0).

Results

The pooled results showed a significant association between rs10069690 and an increased risk of cancer under allele model (OR = 1.10, 95% CI: 1.07–1.13, P < 0.001), especially in European and Asian populations. When stratified by cancer types, this variant was associated with elevated risk of breast cancer (OR = 1.11, 95% CI: 1.07–1.15, P < 0.001), ovarian cancer (OR = 1.14, 95% CI: 1.10–1.19, P < 0.001), lung cancer (OR = 1.20, 95% CI: 1.07–1.35, P = 0.003), thyroid cancer (OR = 1.23, 95% CI: 1.15–1.32, P < 0.001), gastric cancer (OR = 1.31, 95% CI: 1.19–1.45, P < 0.001), and renal cell carcinoma (OR = 1.29, 95% CI: 1.07–1.55, P = 0.007), while decreased risk was found for hepatocellular carcinoma, prostate cancer and pancreatic cancer. Our results also indicated that this variant was significantly associated with solid cancer (OR = 1.11, 95% CI: 1.07–1.14, P < 0.001), but not with hematological tumor.

Conclusion

This systematic meta-analysis demonstrated that the TERT rs10069690 variant was a risk factor for cancer. However, the effects of this variant may vary in different types of cancer and differ across ethnic populations.

Peer Review reports

Introduction

Telomeres are located on the ends of chromosomes which play a crucial role in maintaining chromosome integrity and genomic stability [1]. Telomeres comprise tandem (TTAGGG)n nucleotide repeats and shorten gradually with each cycle of cell division [2]. The shortening of telomeres restricts the proliferation of normal somatic cells. On the contrary, cancer cells can maintain long telomeres and then proliferate indefinitely [3]. It is demonstrated that telomere attrition in leukocytes is inversely correlated with aging, and the length of leucocyte telomere is related with age-related diseases including cancer [4, 5]. As is known now, telomere length is maintained by telomerase, a cellular ribonucleoprotein with reverse transcriptase activity, which is required for synthesis and elongation of telomeric ends. The expression of telomerase is extremely low in most normal somatic cells, but the activation of telomerase is widely observed in malignancies [6]. The human TERT gene at 5p13.33 encodes the telomerase reverse transcriptase (TERT), which is the catalytic subunit of telomerase [7]. As the determining factor for telomerase activity, TERT can exert a significant influence on maintaining cell immortality and cancer development. Genetic variants in the TERT gene were shown to increase the susceptibility to cancer [8]. Common TERT variations were also identified to associate with telomere length in leukocytes [9]. Genome-wide association studies (GWAS) indicated that the 5p13.33 region (harboring the TERT and CLPTM1L genes) was a risk locus for tumor [10, 11]. The TERT rs10069690 (C > T) variant has been found associated with the risk of various types of cancer, such as breast cancer, lung cancer, ovarian cancer, thyroid cancer and gastric cancer [9, 12,13,14]. Nevertheless, there was evidence to the contrary. The study by Lawi et al. demonstrated that there was no significant difference in the allele and genotype distribution of rs10069690 between Iraqi patients with non-small cell lung carcinoma (NSCLC) and healthy controls [15]. Additional reports demonstrated that this variant was not associated with risk of melanoma, endometrial cancer or renal cell carcinoma (RCC) in European population [16,17,18]. Although a meta-analysis has been performed on the overall effect of rs10069690 on cancer risk, multiple lines of new evidence from different tumors and diverse ethnic populations have emerged in recent years [13, 15, 19,20,21,22,23,24,25,26]. To provide a more comprehensive understanding and clarify the inconsistency, we therefore conducted an updated meta-analysis to systematically evaluate the association of the TERT rs10069690 variant with the susceptibility to cancer.

Methods

Identification and eligibility of relevant studies

We performed a comprehensive literature search in PubMed, EMbase, MEDLINE and Cochrane Library without language restriction up to April 30, 2024. Eligible studies were selected based on the PICO (Population, Intervention/exposure, Comparison, Outcome/event) criteria (Supplementary Table S1). The search term included combinations of keywords as follows: “TERT”, “telomerase reverse transcriptase”, “polymorphism”, “single nucleotide polymorphism (SNP)”, “variant”, “rs10069690”, “cancer” and “tumor”. Included studies were required to meet the following criteria: being case-control or cohort studies; investigating the relationship between TERT rs10069690 and the risk of cancer; reporting odds ratios (ORs) with 95% confidence intervals (CIs) or sufficient information for effect size calculation. The titles and abstracts of potential articles were screened by two authors independently. The full-texts of relevant articles were then assessed, while the references of included studies were scrutinized and hand-searched for additional eligible studies. The exclusion criteria were commentaries, reviews, non-research letters, case reports, and studies with overlapping or insufficient data. The detailed strategy of study selection is shown in Fig. 1.

Fig. 1
figure 1

Flowchart of study selection

Full size image

Quality assessment and data extraction

To assess the risk of introducing bias, the 9-point Newcastle–Ottawa Scale (NOS) was used to assess the methodological quality of included studies (0–3 as low; 4–6 as moderate and 7–9 as high quality) [27]. Two authors extracted the data in Excel from all the included studies independently, according to the criteria of inclusion and exclusion. Extracted information includes authorship, country, publication year, study design, cancer type, patient ethnicity, number of cases and controls, genotyping method, and risk estimates with corresponding 95% CIs. Any discrepancies were resolved by discussion and consensus.

Statistical analysis

The association between the TERT rs10069690 variant and cancer risk was estimated in OR with corresponding 95% CIs in the allele model. Subgroup analyses were performed by patient ethnicity (stratified as European, Asian and the others), type of cancer and cancer classification (stratified as solid cancer and hematological tumor). For a certain type of cancer, we also conducted stratified analyses based on patient ethnicity when there was at least one ethnic subgroup including more than 2 studies. Since the rs10069690 variant was reported to be specific to estrogen receptor (ER)-negative breast cancer and triple-negative breast cancer (TNBC), we performed a further analysis based on these two subtypes of breast cancer. Cochran’s Q test and I2 index were calculated to explore heterogeneity across included studies [28]. The DerSimonian-Laird random effects model was used to calculate pooled effect estimates if heterogeneity was present (p < 0.05) [29]. Otherwise, the fixed-effects model was adopted. To assess the stability of the results, a sensitivity analysis was conducted by removing each individual study in turn from the total and reanalyzing the remainder. Egger’s tests and funnel plots were used to identify potential publication bias [30]. Certainty of the evidence was assessed by GRADE approach [31]. Type I error rate was set at 0.05 for two-sided analysis. All statistical analyses were performed using the STATA software (version 11.0).

Results

Characteristics of included studies

A total of 55 studies involving 334,196 patients with cancer and 741,187 controls were finally included in our study [9, 13,14,15,16,17,18, 20,21,22,23,24,25,26, 32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72]. The main characteristics of included studies are shown in Supplementary Table S2. As for methodological quality assessment, 34 studies were awarded ≥ 8 points, and 21 studies were awarded 6 to 7 points, indicating that included studies were of median-to-high quality. When stratified by the types of cancer, there are 12 studies on breast cancer, 7 on lung cancer, 6 on ovarian cancer, 4 on leukemia, 3 on thyroid cancer, 3 on gastric cancer, 2 on hepatocellular carcinoma (HCC), 2 on RCC, 2 on prostate cancer, 2 on pancreatic cancer, 2 on colorectal cancer, 2 on glioma and one each on other eleven kinds of cancers.

Association between rs10069690 and cancer risk

The main results of this meta-analysis were listed in Table 1. Overall, we found the TERT rs10069690 variant was significantly associated with the risk of cancer under allele model (OR = 1.10, 95% CI: 1.07–1.13, P < 0.001; I2 = 89.9%) (Fig. 2). When stratified by ethnicity, we found significant associations between this variant and increased risk of cancer in European population (OR = 1.06, 95% CI: 1.02–1.10, P < 0.001; I2 = 93.0%) and Asians (OR = 1.23, 95% CI: 1.13–1.34, P = 0.004; I2 = 75.0%), but not in other populations (OR = 1.07, 95% CI: 0.97–1.17, P = 0.173; I2 = 89.0%) (Supplementary Figure S1-S3). When stratified by cancer classification, the analysis indicated that the variant was associated with enhanced risk of solid cancer (OR = 1.11, 95% CI: 1.07–1.14, P < 0.001; I2 = 90.2%), rather than hematological tumor (OR = 0.99, 95% CI: 0.85–1.16, P = 0.917; I2 = 88.3%).

Table 1 Main results of the meta-analysis of the association between rs10069690 and cancer risk
Full size table
Fig. 2
figure 2

Forest plot of the association of the TERT rs10069690 variant with overall cancer risk

Full size image

In the subgroup analyses based on cancer type, the rs10069690 variant had significantly associated with an elevated risk of breast cancer (OR = 1.11, 95% CI: 1.07–1.15, P < 0.001; I2 = 86.0%) (Supplementary Figure S4). And then, a further stratified analysis based on histopathological subtypes of breast cancer showed similar results (ER-negative breast cancer: OR = 1.18, 95% CI: 1.15–1.22, P < 0.001, I2 = 48.6%; triple negative breast cancer: OR = 1.24, 95% CI: 1.18–1.31, P < 0.001, I2 = 28.8%) (Supplementary Table S3 and Figure S5-S6). Significant association was also observed for ovarian cancer (OR = 1.14, 95% CI: 1.10–1.19, P < 0.001; I2 = 70.8%), lung cancer (OR = 1.20, 95% CI: 1.07–1.35, P = 0.003; I2 = 56.8%), gastric cancer (OR = 1.31, 95% CI: 1.19–1.45, P < 0.001; I2 = 32.4%), thyroid cancer (OR = 1.23, 95% CI: 1.15–1.32, P < 0.001; I2 = 48.9%) and RCC (OR = 1.29, 95% CI: 1.07–1.55, P = 0.007; I2 = 0%) (Supplementary Figure S7-S11). On the contrary, significant decreased risk was observed for HCC (OR = 0.75, 95% CI: 0.63–0.89, P = 0.001; I2 = 0%), prostate cancer (OR = 0.86, 95% CI: 0.84–0.89, P < 0.001; I2 = 60.6%) and pancreatic cancer (OR = 0.93, 95% CI: 0.87–0.99, P = 0.031; I2 = 0%) (Supplementary Figure S12-S14). There was no significant association found in the pooled analyses for leukemia, colorectal cancer and glioma (Table 1). However, a correlation between this variant and leukemia was identified after removing the study by Bhat et al. [20] (OR = 1.20, 95% CI: 1.14–1.26, P < 0.001; I2 = 0%).

Sensitivity analysis, publication bias and certainty of the evidence

Sensitivity analysis indicated that no single study yield to obvious influence on the pooled ORs, suggesting that these results are robust (Supplementary Figure S15). Egger’s tests and the funnel-plot analysis showed no publication bias detected for the overall meta-analysis (P > 0.05, Supplementary Figure S16). The quality of the evidence was rated as moderate for the overall meta-analysis due to the inconsistency according to the GRADE approach (Supplementary Table S4).

Discussion

In the present study, we performed a meta-analysis to evaluate the impact of TERT rs10069690 variant on cancer susceptibility. The results indicated that this variant was significantly associated with the risk of cancer, which is consistent with previous findings. Due to the ethnic differences, this association retained in Europeans and Asians, but not in other populations. Compared with the previous meta-analysis [19], our study comprised a larger number of studies which allows a more comprehensive assessment. In addition, we performed more refined subgroup analyses based on ethnicity and type/subtype of cancer which provides new insights to the relationship between rs10069690 and cancer risk.

There was substantial heterogeneity in the overall meta-analysis, which was significantly reduced in the subgroup analyses by cancer type. This is plausible that the effects of rs10069690 may vary among different tumors. Previous evidence demonstrated that the risk T allele at rs10069690 resulted in co-production of full-length TERT and an additional splice site in intron 4 of TERT, which created an alternatively splice transcript INS1b [73]. The INS1b transcript encoded a catalytically inactive protein and inhibited the telomerase activity leading to telomere shortening and an increased risk of genetic instability and tumorigenesis. This may explain the T allele is associated with an elevated risk of multiple cancers, which is in line with the results of our analyses for breast cancer, ovarian cancer, lung cancer, thyroid cancer, RCC and gastric cancer. However, it is estimated that activation of telomerase is crucial to cellular immortalization and malignant transformation of cancer cells [6]. In this regard, the T allele at rs10069690 would contribute to a decreased risk of cancer, which is in line with our findings for HCC, prostate cancer and pancreatic cancer. This could be explained by the high complexity of cancer etiology. Meanwhile, the interaction between environmental factors and genetic variants may be another important reason. For example, it has been shown that the expression of TERT and telomerase activity is regulated by estrogen in human ovary [74, 75]. In addition, a prior investigation identified a statistically significant interaction between postmenopausal estrogen-alone therapy and the T allele at rs10069690 with the risk of ovarian cancer [44]. Therefore, future research on potential effect of gene-environment interactions on the development of cancer is warranted.

The rs10069690 variant was previously identified in a GWAS study as a risk variant for ER-negative breast cancer and TNBC [40]. Several lines of evidence confirmed this finding [9, 26, 50]. Although some studies found that this variant was associated with the overall risk of breast cancer, the strength of the association with ER-negative cancer was stronger than ER-positive cancer [41]. Interestingly, one study showed that the rs10069690 variant was associated with a reduced risk for breast cancer in a Mexican population [22]. This might be due to the genetic heterogeneity among different populations. In addition, the relatively small sample size may also contribute to the contradictory result. In the present study, our pooled analysis demonstrated that the T allele of rs10069690 was significantly associated with an elevated risk of overall breast cancer. In the further stratified analyses, we found that there was significant association of this variant with risk of ER-negative breast cancer and TNBC. And the association was greater for TNBC than that for ER-negative breast cancer, in accord with prior findings [40, 46, 50]. ER-negative breast cancer and TNBC are aggressive subtypes of breast cancer, generally associated with a high risk of recurrence and poor prognosis. Further investigation of the relationship between rs10069690 and these tumor subtypes would shed light on the underlying mechanism of tumorigenesis and accelerate the identification of new targets for the therapy of breast cancer.

Lung cancer is the second common diagnosed cancer worldwide, and genetic factors play an important role in its pathogenesis [76]. Numerous genetic loci have been identified to be associated with the susceptibility of lung cancer, including the 5p15.33 locus (TERT- CLPTM1L region) [77, 78]. Some studies reported that the 5p15.33 locus was specifically associated with adenocarcinoma, the most common histologic type of lung cancer [43]. However, other reports suggested the TERT rs10069690 variant was associated with an increased risk of both adenocarcinoma and squamous cell carcinoma subtypes [13]. Our results also supported a significant association between this variant and the total lung cancer cohort. However, due to the lack of detailed clinical information of patients, we were not able to perform the meta-analysis stratified by lung cancer subtypes.

Thyroid cancer is the most common malignancy of endocrine system, which can be classified into four main histology groups: papillary (PTC, 80–85% prevalence), follicular (FTC, 10–15% prevalence), medullary (MTC) and undifferentiated or anaplastic thyroid carcinomas [79, 80]. Our results consisted with prior GWAS and association studies in European and Asian populations [39, 81, 82]. Interestingly, one study indicated that the rs10069690 variant was related to PTC risk, especially in females over 45 years of age [24]. Since sex and age have been identified as risk factors for thyroid cancer [83], further prospective investigations are warranted into the influence of these factors on the association of the rs10069690 variant with thyroid carcinoma.

There were three studies on gastric cancer included in the present study all of which were performed in Chinese population. Our result demonstrated that the rs10069690 T allele was significantly associated with an increased risk of gastric cancer. As for colorectal cancer, HCC, RCC, prostate cancer, pancreatic cancer and glioma, there were only two studies included in the pooled analysis, respectively. Our analysis demonstrated that there was significant association between the rs10069690 variant and an increased risk of RCC. On the contrary, the T allele of rs10069690 was found to associate with decreased risk of HCC, prostate cancer and pancreatic cancer. But due to the limited data and small sample size, the results should be interpreted with caution and further evaluation of the association among different races and ethnic groups is needed. Our result showed no significant association for colorectal cancer and glioma. However, it is worthy to note that this variant might have a significant interaction with lifestyle factors to influence the cancer risk. Individuals with body mass index (BMI) > 30 were found to have an elevated risk of colon cancer in the presence of the T allele of rs10069690 [52]. This finding once again highlights the important role of gene-environmental interaction in the cancer etiology.

When stratified by solid cancer and hematological tumor, there was a significant association for solid cancer, but not for hematological tumor. Interestingly, in the subgroup analysis for leukemia, we found significant association after removing one study and reanalyzing the remaining three studies in European and Asian populations. This study by Bhat et al. investigated the role of the rs10069690 variant in the population of north India, and found a higher frequency of T allele in control group than in case group [20]. This discrepancy could be explained by different genetic background across populations. And our finding suggested that rs10069690 may be a risk factor for leukemia, while its effect in different ethnic groups still needs further research.

There are some limitations in our study. First, we performed this meta-analysis only based on allele model. Due to the lack of detailed genotype data in most studies, we were not able to calculate ORs under other genetic models. Second, substantial or moderate heterogeneity was observed in the pooled analyses. But after stratified by ethnicity and cancer type, most of heterogeneity reduced, indicating that these may be the main source of heterogeneity. Third, the interaction of gene-environment may affect the association of the TERT rs10069690 variant with cancer risk. However, there was no sufficient information, such as age, gender, BMI and status of smoking or drinking, available for us to correct for and perform a more refined analysis.

Conclusion

In conclusion, this comprehensive meta-analysis showed that the TERT rs10069690 variant is associated with cancer risk, especially in European population and Asians. Our results contributed to a better understanding of the effects of this variant on the susceptibility of different types of tumors. For example, this variant was identified to be significantly associated with the risk of gastric cancer, HCC and prostate cancer, which has not been found in previous meta-analysis. These new findings might be helpful to early clinical diagnosis and the selection of treatment strategy for these cancers. Larger studies with detailed clinical and histopathological data, as well as functional studies, are warranted to validate our finding and unveil the underlying mechanism in the future.

Data availability

Data is provided within the manuscript or supplementary information files.

Abbreviations

TERT:

Telomerase reverse transcriptase

NSCLC:

Non-small cell lung carcinoma

RCC:

Renal cell carcinoma

SNP:

Single nucleotide polymorphism

TNBC:

Triple-negative breast cancer

HCC:

Hepatocellular carcinoma

References

  1. Blasco MA. Telomere length, stem cells and aging. Nat Chem Biol. 2007;3(10):640–9.

    Article  CAS  PubMed  Google Scholar 

  2. Autexier C, Lue NF. The structure and function of telomerase reverse transcriptase. Annu Rev Biochem. 2006;75:493–517.

    Article  CAS  PubMed  Google Scholar 

  3. Shay JW, Wright WE. Senescence and immortalization: role of telomeres and telomerase. Carcinogenesis. 2005;26(5):867–74.

    Article  CAS  PubMed  Google Scholar 

  4. Rizvi S, Raza ST, Mahdi F. Telomere length variations in aging and age-related diseases. Curr Aging Sci. 2014;7(3):161–7.

    Article  CAS  PubMed  Google Scholar 

  5. Benetos A, Okuda K, Lajemi M, Kimura M, Thomas F, Skurnick J, et al. Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension. 2001;37(2 Pt 2):381–5.

    Article  CAS  PubMed  Google Scholar 

  6. Zhang A, Zheng C, Lindvall C, Hou M, Ekedahl J, Lewensohn R, et al. Frequent amplification of the telomerase reverse transcriptase gene in human tumors. Cancer Res. 2000;60(22):6230–5.

    CAS  PubMed  Google Scholar 

  7. Liu Y, Snow BE, Hande MP, Yeung D, Erdmann NJ, Wakeham A, et al. The telomerase reverse transcriptase is limiting and necessary for telomerase function in vivo. Curr Biology: CB. 2000;10(22):1459–62.

    Article  CAS  Google Scholar 

  8. Gaspar TB, Sá A, Lopes JM, Sobrinho-Simões M, Soares P, Vinagre J. Telomere maintenance mechanisms in Cancer. Genes. 2018;9(5).

  9. Bojesen SE, Pooley KA, Johnatty SE, Beesley J, Michailidou K, Tyrer JP, et al. Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet. 2013;45(4):371–84. 84e1-2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. McKay JD, Hung RJ, Gaborieau V, Boffetta P, Chabrier A, Byrnes G, et al. Lung cancer susceptibility locus at 5p15.33. Nat Genet. 2008;40(12):1404–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Wang Z, Zhu B, Zhang M, Parikh H, Jia J, Chung CC, et al. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet. 2014;23(24):6616–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Tian J, Wang Y, Dong Y, Chang J, Wu Y, Chang S, et al. Cumulative evidence for relationships between multiple variants in the TERT and CLPTM1L Region and Risk of Cancer and Non-cancer Disease. Front Oncol. 2022;12:946039.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Bhat GR, Jamwal RS, Sethi I, Bhat A, Shah R, Verma S, et al. Associations between telomere attrition, genetic variants in telomere maintenance genes, and non-small cell lung cancer risk in the Jammu and Kashmir population of North India. BMC Cancer. 2023;23(1):874.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Gong L, Xu Y, Hu YQ, Ding QJ, Yi CH, Huang W, et al. hTERT gene polymorphism correlates with the risk and the prognosis of thyroid cancer. Cancer Biomark A. 2016;17(2):195–204.

    Article  CAS  Google Scholar 

  15. Lawi ZK, Alkhammas AH, Elerouri M, Ben AI, Al-Shuhaib MBS. Two co-inherited SNPs of the telomerase reverse transcriptase (TERT) gene are associated with Iraqi patients with lung cancer. J Med Biochem. 2023;42(4):694–705.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Llorca-Cardeñosa MJ, Peña-Chilet M, Mayor M, Gomez-Fernandez C, Casado B, Martin-Gonzalez M, et al. Long telomere length and a TERT-CLPTM1 locus polymorphism association with melanoma risk. Eur J cancer (Oxford England: 1990). 2014;50(18):3168–77.

    Article  Google Scholar 

  17. Prescott J, McGrath M, Lee IM, Buring JE, De Vivo I. Telomere length and genetic analyses in population-based studies of endometrial cancer risk. Cancer. 2010;116(18):4275–82.

    Article  CAS  PubMed  Google Scholar 

  18. de Martino M, Taus C, Lucca I, Hofbauer SL, Haitel A, Shariat SF, et al. Association of human telomerase reverse transcriptase gene polymorphisms, serum levels, and telomere length with renal cell carcinoma risk and pathology. Mol Carcinog. 2016;55(10):1458–66.

    Article  PubMed  Google Scholar 

  19. He G, Song T, Zhang Y, Chen X, Xiong W, Chen H, et al. TERT rs10069690 polymorphism and cancers risk: a meta-analysis. Mol Genet Genom Med. 2019;7(10):e00903.

    Article  Google Scholar 

  20. Bhat A, Bhat GR, Verma S, Sharma B, Bakshi D, Abrol D, et al. Evaluation of 17 genetic variants in association with leukemia in the north Indian population using MassARRAY Sequenom. J Biochem Mol Toxicol. 2021;35(7):e22792.

    Article  CAS  PubMed  Google Scholar 

  21. Dratwa M, Wysoczanska B, Brankiewicz W, Stachowicz-Suhs M, Wietrzyk J, Matkowski R, et al. Relationship between telomere length, TERT Genetic variability and TERT, TP53, SP1, MYC Gene Co-expression in the Clinicopathological Profile of breast Cancer. Int J Mol Sci. 2022;23(9):5164.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Figueroa-González G, Arellano-Gutiérrez CV, Cortés H, Leyva-Gómez G, Carmen MG, Bustamante-Montes LP, et al. Breast cancer-related single-nucleotide polymorphism and their risk contribution in Mexican women. J Cancer Res Ther. 2020;16(6):1279–86.

    Article  PubMed  Google Scholar 

  23. Huang P, Li R, Shen L, He W, Chen S, Dong Y, et al. Single nucleotide polymorphisms in telomere length-related genes are associated with hepatocellular carcinoma risk in the Chinese Han population. Therapeutic Adv Med Oncol. 2020;12:1758835920933029.

    CAS  Google Scholar 

  24. Liu Y, Shi F. Associations of telomerase reverse transcriptase rs10069690 and rs2736100 polymorphisms with papillary thyroid carcinoma. Eur J cancer Prevention: Official J Eur Cancer Prev Organisation (ECP). 2020;29(3):259–65.

    Article  CAS  Google Scholar 

  25. Lili M, Yuxiang F, Zhongcheng H, Ying S, Ru C, Rong X, et al. Genetic variations associated with telomere length affect the risk of gastric carcinoma. Medicine. 2020;99(23):e20551.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Zins K, Peka E, Miedl H, Ecker S, Abraham D, Schreiber M. Association of the Telomerase Reverse Transcriptase rs10069690 polymorphism with the risk, age at Onset and Prognosis of Triple negative breast Cancer. Int J Mol Sci. 2023;24(3).

  27. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.

    Article  PubMed  Google Scholar 

  28. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical Res ed). 2003;327(7414):557–60.

    Article  Google Scholar 

  29. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.

    Article  CAS  PubMed  Google Scholar 

  30. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical Res ed). 1997;315(7109):629–34.

    Article  CAS  Google Scholar 

  31. Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64(4):380–2.

    Article  PubMed  Google Scholar 

  32. Berndt SI, Skibola CF, Joseph V, Camp NJ, Nieters A, Wang Z, et al. Genome-wide association study identifies multiple risk loci for chronic lymphocytic leukemia. Nat Genet. 2013;45(8):868–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Campa D, Martino A, Varkonyi J, Lesueur F, Jamroziak K, Landi S, et al. Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. Int J Cancer. 2015;136(5):E351–8.

    Article  CAS  PubMed  Google Scholar 

  34. Campa D, Rizzato C, Stolzenberg-Solomon R, Pacetti P, Vodicka P, Cleary SP, et al. TERT gene harbors multiple variants associated with pancreatic cancer susceptibility. Int J Cancer. 2015;137(9):2175–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Duan X, Cao W, Wang L, Liu S, Liu Z, Zhang B, et al. Genetic variants in TERT are associated with risk of gastric cancer in a Chinese Han population. Oncotarget. 2016;7(50):82727–32.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Earp M, Winham SJ, Larson N, Permuth JB, Sicotte H, Chien J, et al. A targeted genetic association study of epithelial ovarian cancer susceptibility. Oncotarget. 2016;7(7):7381–9.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Gao L, Thakur A, Liang Y, Zhang S, Wang T, Chen T, et al. Polymorphisms in the TERT gene are associated with lung cancer risk in the Chinese Han population. Eur J cancer Prevention: Official J Eur Cancer Prev Organisation (ECP). 2014;23(6):497–501.

    Article  CAS  Google Scholar 

  38. Garcia-Closas M, Couch FJ, Lindstrom S, Michailidou K, Schmidt MK, Brook MN, et al. Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet. 2013;45(4):392.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Gudmundsson J, Thorleifsson G, Sigurdsson JK, Stefansdottir L, Jonasson JG, Gudjonsson SA, et al. A genome-wide association study yields five novel thyroid cancer risk loci. Nat Commun. 2017;8:14517.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, et al. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet. 2011;43(12):1210–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Huo D, Feng Y, Haddad S, Zheng Y, Yao S, Han YJ, et al. Genome-wide association studies in women of African ancestry identified 3q26.21 as a novel susceptibility locus for oestrogen receptor negative breast cancer. Hum Mol Genet. 2016;25(21):4835–46.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Kuchenbaecker KB, Ramus SJ, Tyrer J, Lee A, Shen HC, Beesley J, et al. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nat Genet. 2015;47(2):164–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, Rotunno M, et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet. 2009;85(5):679–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Lee AW, Bomkamp A, Bandera EV, Jensen A, Ramus SJ, Goodman MT, et al. A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. Int J Cancer. 2016;139(12):2646–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Li C, Zhao Z, Zhou J, Liu Y, Wang H, Zhao X. Relationship between the TERT, TNIP1 and OBFC1 genetic polymorphisms and susceptibility to colorectal cancer in Chinese Han population. Oncotarget. 2017;8(34):56932–41.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Long J, Zhang B, Signorello LB, Cai Q, Deming-Halverson S, Shrubsole MJ, et al. Evaluating genome-wide association study-identified breast cancer risk variants in African-American women. PLoS ONE. 2013;8(4):e58350.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Melin BS, Barnholtz-Sloan JS, Wrensch MR, Johansen C, Il’yasova D, Kinnersley B, et al. Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat Genet. 2017;49(5):789–94.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Michailidou K, Beesley J, Lindstrom S, Canisius S, Dennis J, Lush MJ, et al. Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nat Genet. 2015;47(4):373–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Michailidou K, Lindström S, Dennis J, Beesley J, Hui S, Kar S, et al. Association analysis identifies 65 new breast cancer risk loci. Nature. 2017;551(7678):92–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Palmer JR, Ruiz-Narvaez EA, Rotimi CN, Cupples LA, Cozier YC, Adams-Campbell LL, et al. Genetic susceptibility loci for subtypes of breast cancer in an African American population. Cancer Epidemiol Biomarkers Prevention: Publication Am Association Cancer Res Cosponsored Am Soc Prev Oncol. 2013;22(1):127–34.

    Article  CAS  Google Scholar 

  51. Panagiotou OA, Travis RC, Campa D, Berndt SI, Lindstrom S, Kraft P, et al. A genome-wide pleiotropy scan for prostate cancer risk. Eur Urol. 2015;67(4):649–57.

    Article  PubMed  Google Scholar 

  52. Pellatt AJ, Wolff RK, Herrick J, Lundgreen A, Slattery ML. TERT’s role in colorectal carcinogenesis. Mol Carcinog. 2013;52(7):507–13.

    Article  CAS  PubMed  Google Scholar 

  53. Petersen GM, Amundadottir L, Fuchs CS, Kraft P, Stolzenberg-Solomon RZ, Jacobs KB, et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet. 2010;42(3):224–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Phelan CM, Kuchenbaecker KB, Tyrer JP, Kar SP, Lawrenson K, Winham SJ, et al. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017;49(5):680–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Purrington KS, Slager S, Eccles D, Yannoukakos D, Fasching PA, Miron P, et al. Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis. 2014;35(5):1012–9.

    Article  CAS  PubMed  Google Scholar 

  56. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, et al. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet. 2010;42(11):978–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Schumacher FR, Berndt SI, Siddiq A, Jacobs KB, Wang Z, Lindstrom S, et al. Genome-wide association study identifies new prostate cancer susceptibility loci. Hum Mol Genet. 2011;20(19):3867–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Schumacher FR, Wang Z, Skotheim RI, Koster R, Chung CC, Hildebrandt MA, et al. Testicular germ cell tumor susceptibility associated with the UCK2 locus on chromosome 1q23. Hum Mol Genet. 2013;22(13):2748–53.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Shadrina AS, Boyarskikh UA, Oskina NA, Sinkina TV, Lazarev AF, Petrova VD, et al. TERT polymorphisms rs2853669 and rs7726159 influence on prostate cancer risk in Russian population. Tumor Biology. 2015;36(2):841–7.

    Article  CAS  PubMed  Google Scholar 

  60. Sheng X, Tong N, Tao G, Luo D, Wang M, Fang Y, et al. TERT polymorphisms modify the risk of acute lymphoblastic leukemia in Chinese children. Carcinogenesis. 2013;34(1):228–35.

    Article  CAS  PubMed  Google Scholar 

  61. Speedy HE, Di Bernardo MC, Sava GP, Dyer MJ, Holroyd A, Wang Y, et al. A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia. Nat Genet. 2014;46(1):56–60.

    Article  CAS  PubMed  Google Scholar 

  62. Terry KL, Tworoger SS, Vitonis AF, Wong J, Titus-Ernstoff L, De Vivo I et al. Telomere length and genetic variation in telomere maintenance genes in relation to ovarian cancer risk. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2012;21(3):504–12.

  63. Wang H, Yang H, Feng T, Geng T, Chen C, Jin T. Effects of TERT gene polymorphism and environmental factor interactions on lung cancer risk in the Xi’an Han population. Int J Clin Exp Med. 2016;9(2):4200–10.

    CAS  Google Scholar 

  64. Wu D, Zhu G, Zeng J, Song W, Wang K, Wang X, et al. Genetic variations in TERC and TERT genes are associated with renal cell carcinoma risk in a Chinese Han population. Oncotarget. 2017;8(44):76832–42.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Wu Y, Yan M, Li J, Li J, Chen Z, Chen P, et al. Genetic polymorphisms in TERT are associated with increased risk of esophageal cancer. Oncotarget. 2017;8(6):10523–30.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Ye G, Tan N, Meng C, Li J, Jing L, Yan M, et al. Genetic variations in TERC and TERT genes are associated with lung cancer risk in a Chinese Han population. Oncotarget. 2017;8(66):110145–52.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Zhang R, Zhao J, Xu J, Liu F, Xu Y, Bu X, et al. Genetic variations in the TERT and CLPTM1L gene region and gastrointestinal stromal tumors risk. Oncotarget. 2015;6(31):31360–7.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Zhang Y, Wang S, Shi Y, Cao Y, He H, Zhou S, et al. Associations of TERT polymorphisms with hepatocellular carcinoma risk in a Han Chinese population. Int J Clin Exp Pathol. 2017;10(7):7776–83.

    PubMed  PubMed Central  Google Scholar 

  69. Zhang Y, Zhang X, Zhang H, Zhai Y, Wang Z, Li P, et al. Common variations in TERT-CLPTM1L locus are reproducibly associated with the risk of nasopharyngeal carcinoma in Chinese populations. Oncotarget. 2016;7(1):759–70.

    Article  PubMed  Google Scholar 

  70. Zhang N, Zheng Y, Liu J, Lei T, Xu Y, Yang M. Genetic variations associated with telomere length confer risk of gastric cardia adenocarcinoma. Gastric cancer: Official J Int Gastric Cancer Association Japanese Gastric Cancer Association. 2019;22(6):1089–99.

    Article  CAS  Google Scholar 

  71. Zhao Y, Chen G, Zhao Y, Song X, Chen H, Mao Y, et al. Fine-mapping of a region of chromosome 5p15.33 (TERT-CLPTM1L) suggests a novel locus in TERT and a CLPTM1L haplotype are associated with glioma susceptibility in a Chinese population. Int J Cancer. 2012;131(7):1569–76.

    Article  CAS  PubMed  Google Scholar 

  72. Zhao Z, Li C, Yang L, Zhang X, Zhao X, Song X, et al. Significant association of 5p15.33 (TERT-CLPTM1L genes) with lung cancer in Chinese Han population. Exp Lung Res. 2013;39(2):91–8.

    Article  CAS  PubMed  Google Scholar 

  73. Killedar A, Stutz MD, Sobinoff AP, Tomlinson CG, Bryan TM, Beesley J, et al. A Common Cancer Risk-Associated Allele in the hTERT Locus encodes a Dominant negative inhibitor of telomerase. PLoS Genet. 2015;11(6):e1005286.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Liu JP, Li H. Telomerase in the ovary. Reprod (Cambridge England). 2010;140(2):215–22.

    Article  CAS  Google Scholar 

  75. Misiti S, Nanni S, Fontemaggi G, Cong YS, Wen J, Hirte HW, et al. Induction of hTERT expression and telomerase activity by estrogens in human ovary epithelium cells. Mol Cell Biol. 2000;20(11):3764–71.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. Cancer J Clin. 2021;71(3):209–49.

    Article  Google Scholar 

  77. Broderick P, Wang Y, Vijayakrishnan J, Matakidou A, Spitz MR, Eisen T, et al. Deciphering the impact of common genetic variation on lung cancer risk: a genome-wide association study. Cancer Res. 2009;69(16):6633–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Hsiung CA, Lan Q, Hong YC, Chen CJ, Hosgood HD, Chang IS et al. The 5p15.33 locus is associated with risk of lung adenocarcinoma in never-smoking females in Asia. PLoS Genet. 2010;6(8).

  79. Raman P, Koenig RJ. Pax-8-PPAR-γ fusion protein in thyroid carcinoma. Nat Reviews Endocrinol. 2014;10(10):616–23.

    Article  CAS  Google Scholar 

  80. Soares P, Póvoa AA, Melo M, Vinagre J, Máximo V, Eloy C, et al. Molecular Pathology of non-familial follicular epithelial-derived thyroid Cancer in adults: from RAS/BRAF-like Tumor designations to Molecular Risk Stratification. Endocr Pathol. 2021;32(1):44–62.

    Article  CAS  PubMed  Google Scholar 

  81. Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Masson G, He H, et al. Discovery of common variants associated with low TSH levels and thyroid cancer risk. Nat Genet. 2012;44(3):319–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  82. Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Sigurdsson A, Bergthorsson JT, et al. Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat Genet. 2009;41(4):460–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Boucai L, Zafereo M, Cabanillas ME. Thyroid Cancer: Rev Jama. 2024;331(5):425–35.

    CAS  Google Scholar 

Download references

Acknowledgements

None.

Funding

This work was supported by grant from the Natural Science Foundation of Shanghai (21ZR1433000), Natural Science Foundation of Chongqing (cstc2021jcyj-msxmX0674), Ministry of Education of the People’s Republic of China, University-Industry Collaborative Education Program of China (220604408010836), Nurture projects for basic research of Shanghai Chest Hospital (2021YNJCM01) and Laboratory of Ecological Security and Biodiversity Conservation of Cities on the Yangtze River Delta, Shanghai Science and Technology Museum.

Author information

Authors and Affiliations

  1. Department of Thoracic Surgery, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200030, China

    Chao Zhou

  2. Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education), Shanghai Jiao Tong University, Shanghai, 200030, China

    Yunke Yang, Lu Shen, Lu Wang, Juan Zhang & Xi Wu

Authors
  1. Chao Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yunke Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lu Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Juan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xi Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization: XW; Data collection and extraction: CZ, YY, LS, LW and JZ; Data analysis and interpretation: CZ and XW; Manuscript writing: CZ and XW; Manuscript editing: XW. All authors have read and approved the final manuscript.

Corresponding author

Correspondence to Xi Wu.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, C., Yang, Y., Shen, L. et al. Association of telomerase reverse transcriptase gene rs10069690 variant with cancer risk: an updated meta-analysis. BMC Cancer 24, 1059 (2024). https://doi.org/10.1186/s12885-024-12833-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12885-024-12833-2

Keywords

BMC Cancer

ISSN: 1471-2407

Contact us